These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 31211856)

  • 1. Identification of a Pan-Gamma-Secretase Inhibitor Response Signature for Notch-Driven Cholangiocarcinoma.
    O'Rourke CJ; Matter MS; Nepal C; Caetano-Oliveira R; Ton PT; Factor VM; Andersen JB
    Hepatology; 2020 Jan; 71(1):196-213. PubMed ID: 31211856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.
    Meng X; Matlawska-Wasowska K; Girodon F; Mazel T; Willman CL; Atlas S; Chen IM; Harvey RC; Hunger SP; Ness SA; Winter SS; Wilson BS
    Leukemia; 2011 Jul; 25(7):1135-46. PubMed ID: 21494254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cervical Cancer Cell Growth, Drug Resistance, and Epithelial-Mesenchymal Transition Are Suppressed by y-Secretase Inhibitor RO4929097.
    Wang L; Dai G; Yang J; Wu W; Zhang W
    Med Sci Monit; 2018 Jun; 24():4046-4053. PubMed ID: 29899322
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant activation of Notch signaling in extrahepatic cholangiocarcinoma: clinicopathological features and therapeutic potential for cancer stem cell-like properties.
    Aoki S; Mizuma M; Takahashi Y; Haji Y; Okada R; Abe T; Karasawa H; Tamai K; Okada T; Morikawa T; Hayashi H; Nakagawa K; Motoi F; Naitoh T; Katayose Y; Unno M
    BMC Cancer; 2016 Nov; 16(1):854. PubMed ID: 27821106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Crenigacestat, a selective NOTCH1 inhibitor, reduces intrahepatic cholangiocarcinoma progression by blocking VEGFA/DLL4/MMP13 axis.
    Mancarella S; Serino G; Dituri F; Cigliano A; Ribback S; Wang J; Chen X; Calvisi DF; Giannelli G
    Cell Death Differ; 2020 Aug; 27(8):2330-2343. PubMed ID: 32042099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition.
    Han J; Ma I; Hendzel MJ; Allalunis-Turner J
    Breast Cancer Res; 2009; 11(4):R57. PubMed ID: 19660128
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.
    Saito N; Fu J; Zheng S; Yao J; Wang S; Liu DD; Yuan Y; Sulman EP; Lang FF; Colman H; Verhaak RG; Yung WK; Koul D
    Stem Cells; 2014 Jan; 32(1):301-12. PubMed ID: 24038660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Notch signaling is required for cholangiocarcinoma progression and is enhanced by inactivation of p53 in vivo.
    El Khatib M; Bozko P; Palagani V; Malek NP; Wilkens L; Plentz RR
    PLoS One; 2013; 8(10):e77433. PubMed ID: 24204826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. De novo discovery of a gamma-secretase inhibitor response signature using a novel in vivo breast tumor model.
    Watters JW; Cheng C; Majumder PK; Wang R; Yalavarthi S; Meeske C; Kong L; Sun W; Lin J; Heyer J; Ware C; Winter C; Reilly JF; Demuth T; Clark S; Chiu MI; Robinson MO; Kohl N; Kannan K
    Cancer Res; 2009 Dec; 69(23):8949-57. PubMed ID: 19903844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
    Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
    Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
    Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
    J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of gamma-secretase affects proliferation of leukemia and hepatoma cell lines through Notch signaling.
    Suwanjunee S; Wongchana W; Palaga T
    Anticancer Drugs; 2008 Jun; 19(5):477-86. PubMed ID: 18418214
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo manifestation of Notch related phenotypes in zebrafish treated with Alzheimer's amyloid reducing gamma-secretase inhibitors.
    Yang T; Arslanova D; Xu X; Li YM; Xia W
    J Neurochem; 2010 Jun; 113(5):1200-9. PubMed ID: 20345767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
    Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. γ-Secretase inhibitor enhances antitumour effect of radiation in Notch-expressing lung cancer.
    Mizugaki H; Sakakibara-Konishi J; Ikezawa Y; Kikuchi J; Kikuchi E; Oizumi S; Dang TP; Nishimura M
    Br J Cancer; 2012 Jun; 106(12):1953-9. PubMed ID: 22596234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of gamma-secretase activity impedes uterine serous carcinoma growth in a human xenograft model.
    Groeneweg JW; Hall TR; Zhang L; Kim M; Byron VF; Tambouret R; Sathayanrayanan S; Foster R; Rueda BR; Growdon WB
    Gynecol Oncol; 2014 Jun; 133(3):607-15. PubMed ID: 24667249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting γ-secretases protect against angiotensin II-induced cardiac hypertrophy.
    Rivera-Torres J; Guzmán-Martínez G; Villa-Bellosta R; Orbe J; González-Gómez C; Serrano M; Díez J; Andrés V; Maraver A
    J Hypertens; 2015 Apr; 33(4):843-50; discussion 850. PubMed ID: 25915889
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GSI-I has a better effect in inhibiting hepatocellular carcinoma cell growth than GSI-IX, GSI-X, or GSI-XXI.
    Shen Y; Lv D; Wang J; Yin Y; Miao F; Dou F; Zhang J
    Anticancer Drugs; 2012 Aug; 23(7):683-90. PubMed ID: 22569108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of gamma-secretase activity inhibits tumor progression in a mouse model of pancreatic ductal adenocarcinoma.
    Plentz R; Park JS; Rhim AD; Abravanel D; Hezel AF; Sharma SV; Gurumurthy S; Deshpande V; Kenific C; Settleman J; Majumder PK; Stanger BZ; Bardeesy N
    Gastroenterology; 2009 May; 136(5):1741-9.e6. PubMed ID: 19208345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma.
    Stoeck A; Lejnine S; Truong A; Pan L; Wang H; Zang C; Yuan J; Ware C; MacLean J; Garrett-Engele PW; Kluk M; Laskey J; Haines BB; Moskaluk C; Zawel L; Fawell S; Gilliland G; Zhang T; Kremer BE; Knoechel B; Bernstein BE; Pear WS; Liu XS; Aster JC; Sathyanarayanan S
    Cancer Discov; 2014 Oct; 4(10):1154-67. PubMed ID: 25104330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.